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As the need to develop a successful disease-modifying treatment for Alzheimer’s disease (AD) becomes more urgent,
imaging is increasingly used in therapeutic trials. We provide an overview of how the different imaging modalities are
used in AD studies and the current regulatory guidelines for their use in clinical trials as endpoints. We review the
current literature for results of imaging endpoints of efficacy and safety in published clinical trials. We start with trials in
mild to moderate AD, where imaging (largely magnetic resonance imaging (MRI)) has long played a role in inclusion
and exclusion criteria; more recently, MRI has been used to identify adverse events and to measure rates of brain
atrophy. The advent of amyloid imaging using positron emission tomography has led to trials incorporating
amyloid measurements as endpoints and incidentally to the recognition of the high proportion of amyloid-negative
individuals that may be recruited into these trials. Ongoing and planned trials now commonly include multimodality
imaging: amyloid positron emission tomography, MRI and other modalities. At the same time, the failure of recent large
profile trials in mild to moderate AD together with the realisation that there is a long prodromal period to AD has
driven a push to move studies to earlier in the disease. Imaging has particularly important roles, alongside other
biomarkers, in assessing efficacy because conventional clinical outcomes may have limited ability to detect treatment
effects in these early stages.Introduction
Treatments for Alzheimer’s disease (AD) and related dis-
orders are currently limited to those that provide only
modest symptomatic benefit. Disease-modifying therap-
ies are urgently needed, especially those that would delay
the onset of clinical decline. An effective treatment that
delays symptom onset by 5 years has been estimated to
potentially reduce predicted dementia prevalence and
healthcare costs by 40 to 50% [1]. A large number of
candidate disease-modifying therapies are under devel-
opment [2]; the studies that will be assessing these therap-
ies are increasingly incorporating a range of imaging and
other biomarkers to understand better their effects and to
show evidence of disease slowing. This evidence is par-
ticularly important for guiding decisions about which
therapies to take forward into large and expensive late-
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unless otherwise stated.Imaging endpoints provide at least three possible bene-
fits to clinical trials in dementia. First, they provide a
means of assessing potential disease-modifying effects and
differentiating these from symptomatic benefits that do
not affect underlying pathological progression. Many im-
aging biomarkers have been shown to correlate with dis-
ease severity, as well as predict future progression in
subjects yet to show clinical symptoms. Second, the quan-
titative nature of the imaging biomarkers often have far
less variability than the primary cognitive and functional
endpoints, and thus will require smaller sample sizes to be
powered to show a statistically significant effect. These
quantitative endpoints are objective measures where the
data can be saved for further re-analysis, while assess-
ments of clinical status are more subjective and cannot be
revisited at a later stage. Finally, imaging can be used in
assessing the safety of a treatment, potentially identifying
adverse effects before symptoms are reported by patients.
This article provides an overview of how imaging has
been used as an endpoint in clinical trials in AD. We
assessed published studies and also the controlled clinical
trials database ClinicalTrials.gov. This review includes tri-
als in mild to moderate AD, newer trials involving patientsd. The licensee has exclusive rights to distribute this article, in any medium, for
time, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(secondary) prevention to slow the onset of clinical AD in
preclinical populations. In more recent trials and in those
with a focus earlier in the disease, study designs rely more
on imaging to select populations and to help assess safety
and efficacy, although imaging still provides secondary or
exploratory endpoints. Finally, we describe the regulatory
guidance on how these biomarkers should be used in
trials.
Review
Imaging biomarkers in Alzheimer’s disease
The most commonly used imaging modality in the study
of AD has been volumetric T1-weighted magnetic reson-
ance imaging (MRI). These images provide high-resolution
(~1 mm) structural images with good tissue contrast. Lon-
gitudinal natural history cohort studies have demonstrated
changes in global measures based on T1 images, such as
whole brain volume or ventricular volume, as well as re-
gional measures, particularly the hippocampus, that are
several times higher in AD patients than in age-matched
cognitively intact individuals. These studies have typically
shown greater effect sizes and therefore lower samples
sizes for imaging when compared with clinical endpoints.
In a 38-centre imaging continuation of a therapeutic
trial of milameline [3], the estimated number of subjects
per arm required to detect a 50% reduction in the rate
of decline over 1 year was only 21 for hippocampal vol-
ume compared with 320 for the Alzheimer’s Disease As-
sessment Scale – cognitive subscale and 241 for the
Mini Mental State Examination. Similar improvements
in sample sizes needed to power for a reasonable treat-
ment effect were observed in the large Alzheimer’s Disease
Neuroimaging Initiative study, where numerous studies
using different atrophy measurement techniques have pro-
duced sample size estimates in the order of 100 to 200 per
arm needed for an AD trial with 80% power to detect a
25% improvement in annual rate of decline [4-6]. Note that
this 25% improvement in an imaging biomarker may not
relate to a 25% improvement in clinical measures. A
complete review of sample size estimates from the Alzhei-
mer’s Disease Neuroimaging Initiative can be found in [7].
Similar sample size estimates for a MCI trial would be
higher, in the order of 300 to 600 per arm, and very
dependent on inclusion criteria. Such studies led to the in-
creased inclusion of volumetric measures as endpoints in
clinical trials.
As with volumetric MRI, fludeoxyglucose (FDG)-based
positron emission tomography (PET) has been extensively
investigated in natural history studies of AD, revealing
characteristic and progressive reductions in regional mea-
surements of the cerebral metabolic rate for glucose, par-
ticularly involving the posterior cingulate, parietal and
temporal regions. The statistical power of FDG-PET todetect the ability of a putative disease-modifying therapy
to slow rates of regional decline in randomised clinical tri-
als has been estimated, with the number of AD patients
per treatment arm needed to detect an effect with FDG-
PET being either greater than or similar to that needed
with MRI [8], roughly 200 per arm for AD [9].
Another family of PET radiotracers that shows great
utility for AD research is the ligands that bind to fibrillar
forms of amyloid beta. The initial amyloid PET imaging
studies were performed using the carbon-11-based lig-
and Pittsburgh compound B (PIB). These studies, along
with data from cerebrospinal fluid (CSF) measurements
of amyloid beta 1-42, provided further evidence that the
disease process begins years before symptoms are ob-
served clinically. These measures of amyloid burden pro-
vided in vivo support for a clinical diagnosis of AD. Due
to the short (20 minutes) half-life of carbon-11, multi-
centre studies using this tracer can be challenging. A
number of fluorine-18-based amyloid tracers have since
been developed; due to the longer (110 minutes) half-
life, using these tracers does not require a cyclotron on
site. There is currently limited information regarding
sample size estimates for amyloid imaging.
An alternative to amyloid imaging is CSF biomarkers,
with a low CSF amyloid beta 1-42 level having similar
sensitivity for cerebral amyloid deposition. CSF examina-
tions do not provide the ability to quantify regional de-
position, but they are more readily available and do
allow for assessment of other markers of pathology
within a single (admittedly invasive) assessment: CSF
total tau and phosphor-tau being important markers of
neurodegeneration. In terms of application to clinical
trials, CSF biomarkers can be either complementary or
an alternative to amyloid imaging depending on use.
There is also evidence that the two measures might be
interchangeable for the purpose of inclusion criteria
for some trials, as there is good agreement between
CSF and PET measures, which have a strong inverse
correlation [10-12]. For more information on the utility
of CSF biomarkers, the authors would refer the readers to
the review article by Blennow and colleagues [13].
While the previous imaging modalities are used for
biomarkers of efficacy, MRI scans can also be used for
safety endpoints in trials. In particular in some anti-
amyloid immunotherapy trials, a number of patients de-
veloped side effects associated with what has been
termed amyloid-related imaging abnormalities (ARIA).
Two major types of ARIA have been described: ARIA-E, sig-
nal hyperintensities seen on T2-weighted fluid-attenuated
inversion recovery magnetic resonance sequences felt to
represent vasogenic oedema and/or sulcal effusion; and
ARIA-H, signal hypointensities on T2*-weighted gradient
recalled echo magnetic resonance sequences that are
thought to represent haemosiderin deposits including
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safety assessments have become an essential aspect of
clinical trials in AD, a rating scale has been developed to
help standardise these measures [15].
Search strategy
The data search was completed on 15 May 2014 using
the PubMed and ClinicalTrials.gov databases.
The PubMed search was used to find all published re-
sults from completed clinical trials where imaging was
used as an endpoint. For the PubMed search, two Med-
ical Subject Headings terms were used for the disease:
‘Alzheimer disease/drug therapy’ or ‘Mild Cognitive Im-
pairment/drug therapy’. These were combined with the
following outcome-related Medical Subject Headings
terms: ‘Biological Markers/analysis’, ‘Biological Markers/
drug effects’, ‘magnetic resonance imaging’ and ‘positron
emission tomography’. Only publications tagged as a
Clinical Trial Medical Subject Headings publication type
were considered. The resulting literature search was lim-
ited to the last 10 years of publication date and all articles
were reviewed for relevance, including only publications
where imaging was used as an endpoint for the study. Im-
aging studies that used voxel-wise analysis with no specific
measurable quantity were excluded because they would
not be suitable as an endpoint for a trial.
The search on ClinicalTrials.gov was used to deter-
mine those completed and currently active clinical trials
in AD and MCI in which imaging was an endpoint listed
in the trial entry. ‘Alzheimer disease’ and ‘mild cognitive
impairment’ were used as the search terms in the condi-
tion field, and the following search terms were used for
the outcomes: ‘MRI’, ‘PET’, ‘magnetic resonance imaging’,
‘positron emission tomography’, ‘hippocampal volume’,
‘brain volume’ and ‘brain atrophy’ – only trials active
within the last 10 years were considered. The resulting
trial entries were also reviewed for relevance. The results
from both searches were combined into Additional file 1.
Mild to moderate Alzheimer’s disease
Most of the reviewed trials in dementia have enrolled a
population diagnosed with probable AD according to a
standard diagnostic criterion, such as that of the Na-
tional Institute of Neurological and Communicative
Disorders and Stroke–Alzheimer’s Disease and Related
Disorders Association working group [16]. Most studies
recruit patients either with mild or mild/moderate sever-
ity, primarily determined by a range of Mini Mental State
Examination scores.
Magnetic resonance imaging as a safety endpoint
Although imaging has long been used to assess adverse
events in trials in AD, this was largely in the investigation
of a symptomatic event (for example, a cerebrovascularevent). More recently the introduction of very biologically
active therapies for AD has led to increased use of MRI as
a proactive safety assessment. One of the drivers for the
increased use of MRI as a safety endpoint was the (inter-
rupted) trial of active anti-amyloid vaccination (AN-1792),
where there were reports of meningoencephalitis in ~6%
(18/300) of immunised participants in the treatment arm
[17,18]. Active vaccination with the CAD106 vaccine had
three adverse events out of 46 participants based on MRI
findings, although none were considered serious or associ-
ated with the central nervous system changes that sug-
gested meningitis or encephalitis [19].
Subsequent to the AN1792 study, the majority of im-
munotherapy trials have used passive rather than active
immunotherapy, and imaging is now necessary as a
safety endpoint due to the risk of ARIA. ARIA was ob-
served in a phase I study for bapineuzumab [20] and in
subsequent phase II [21] and phase III [22] studies,
where dose and the presence of an ε4 allele of the apoli-
poprotein E (ApoE) gene appeared to be risk factors
[23]. ARIA-E findings have also been reported in sub-
jects from a phase II study of gantenerumab [24] and a
phase II study of the gamma secretase inhibitor avegace-
stat [25]. Trials of two monoclonal antibodies, ponezu-
mab [26,27] and solanezumab [28,29], the nonselective
gamma secretase inhibitor semagacesat [30], the anti-
amyloid aggregation agent scyllo-inositol [31] and the
intravenous immunoglobulin administration Octagam
[32] have used MRI for safety endpoints and showed
no significant treatment-related findings of ARIA.
Structural magnetic resonance imaging as an efficacy
endpoint
Numerous clinical trials of a wide range of compounds in
AD have reported imaging endpoints based on structural
MRI. A summary of findings is presented in Table 1.
Numerous studies showed no significant treatment ef-
fects of any atrophy-related outcome measure: docosa-
hexaenoic acid [33], intravenous immunoglobulin [32]
and rosiglitazone [34]. Given the sample size estimates
from the Alzheimer’s Disease Neuroimaging Initiative
discussed previously, it could be argued that many of
these studies were underpowered for the atrophy measure.
The recent high-profile phase III studies involving sema-
gacestat [30] and solaneuzumab [29] also showed no sta-
tistically significant effect of treatment. In some cases, a
treatment effect opposite to the expected direction – a
phenomenon that has been referred to as paradoxical
volume loss – was observed.
The most commonly used atrophy measure in clinical
trials is a global measure of whole brain atrophy. In the
AN-1792 study, unexpected (or paradoxical) increased
brain volume loss was observed in the antibody re-
sponders and there was a strong association between
Table 1 Published results of clinical trials in mild to moderate Alzheimer’s disease where volumetric magnetic
resonance imaging was used as an imaging endpoint
Compound Subject numbers Follow-up duration
(months)
Treatment effect
Placebo arm Treatment arm
AN-1792 [35] 57 231a 11 Ventricles (⇑), whole brain atrophy (⇑, antibody
responders only), hippocampus (⇔)
Atorvastatin and donepezil [38] 64b 18 Whole brain (⇔), hippocampus (⇓)
Bapineuzumab (phase II) [21] 122 107 18 Whole brain (⇓, in ε4 noncarriers)c, ventricles
(⇑, in ε4 carriers)d
Bapineuzumab (phase III) ε4
carriers [22]
238 352 18 Whole brain (⇔)
Bapineuzumab (phase III) ε4
noncarriers [22]
244 315e 18 Whole brain (⇔)
CAD106 [19] 7/5 24/21f 6, 12 Whole brain (⇔)g, ventricles (⇔), hippocampus (⇓)h
Docosahexaenoic acid [33] 49 53 18 Whole brain (⇔), ventricles (⇔), hippocampus (⇔)
Intravenous immunoglobulin [32] 7 21 3, 6 Whole brain (⇔), hippocampus (⇔)
Memantine [40] 40i 12 Whole brain (⇔), ventricles (⇔), hippocampus
(⇓, right only)
Memantine [41] 118 110 12 Whole brain (⇔), hippocampus (⇔)
Rosiglitazone [34] 38 38 6, 12 Whole brain (⇔)
Scyllo-inositol [31] 83 259 18 Whole brain (⇔), ventricles (⇑), hippocampi (⇔)
Semagacestat [30] 208b 18 Whole brain (⇔), hippocampus (⇔)
Solaneuzumab [29] 370/400j 370/406 18 Whole brain (⇔), hippocampus (⇔)
Tramiprosate [45,46] 109 203k 18 Hippocampus (⇓)l
⇑, Treatment effect of increased atrophy (or ventricular enlargement); ⇓, treatment effect of decreased atrophy (or ventricular enlargement); ⇔, no treatment
effect found. aOf these 231 subjects in the treatment arm, 45 were antibody responders. bThe number of subjects enrolled in the magnetic resonance imaging
substudy does not identify a division between the placebo arm and the treatment arm, thus the number in the cell indicates the total number of subjects over
both arms. cLess brain atrophy (10.7 ml over 71-week follow-up) in apolipoprotein E noncarriers receiving bapineuzumab. dMore ventricular enlargement (2.6 ml
over 71 week follow-up) in apolipoprotein E carriers receiving bapineuzumab. eThe 315 subjects consisted of 169 at 0.5 mg/kg dose and 146 at 1.0 mg/kg dose.
fThe CAD106 study had two cohorts, where the treatment arm dosage was different (Cohort I, 50 μg; Cohort II, 150 μg). gOne global measure of atrophy, left
cerebral white matter, did show a treatment effect in Cohort I, but this did not survive correction for multiple comparisons. hIn Cohort I, the right hippocampus
showed a treatment effect and left hippocampus showed a trend towards treatment effects, but these did not survive multiple comparisons. iSingle-group open-label
study where subjects had a 24-week lead-in period, followed by 24 weeks treatment of memantine. jThe publication consisted of two phase III studies, neither of which
showed any treatment effects. kTwo treatment arms: 103 subjects at 100 mg twice daily, 100 subjects at 150 mg twice daily. lOriginal model showed no treatment
effects, but post-hoc analysis putting in site as a random effect and important covariates showed a treatment effect.
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erated the higher titres of antibodies had greater volume
loss [35]. In a very small subset of study participants
who underwent longer term follow-up scans 4.5 years
after baseline, this increase in atrophy was no longer
present [36]. While a phase II study of bapineuzumab
showed no treatment effect in whole brain atrophy,
there was a substantial treatment effect (10.7 ml/year)
observed when restricting the analysis to APOE ε4 non-
carriers only [21]. This finding was not replicated in the
larger phase III study of noncarriers [22].
Ventricular enlargement can be a sensitive (although
nonspecific) volumetric measure in dementia. Increased
ventricular expansion was seen in the AN-1792 study
with some suggestion of greater ventricular expansion
relative to global brain loss. A similar finding was also
observed in a phase II study of scyllo-inositol, although
the finding (3.2 ml/year increase, P = 0.049) was not cor-
rected for multiple comparisons and no other measures(whole brain, hippocampus and cortical thickness) showed
any treatment effects [31]. The phase II study of bapineu-
zumab showed greater ventricular enlargement, but in ε4
carriers only [21]. This was also found in the two phase III
studies, although the increase was much smaller [37].
Measures of medial temporal lobe atrophy (hippocampi,
entorhinal cortex) are far more specific to AD. In the
AN1792 study, antibody responders also exhibited in-
creased hippocampal atrophy, but this finding was not sta-
tistically significant. In one of the cohorts of the CAD106
vaccine, a slowing of hippocampal atrophy was seen in
one of the cohorts, but this did not survive correction for
multiple comparisons. Two studies of atorvastatin both
observed treatment effects of reduced hippocampal at-
rophy, albeit with caveats. In the LEADe study [38],
there were significant baseline differences in demo-
graphics as well as the Alzheimer's Disease Cooperative
Study – Clinical Global Impression of Change score,
which was one of the co-primary outcomes. In the
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did not reach statistical significance and was based pri-
marily on right hippocampal volume [39].
In a phase IV, open-label single-group study of mem-
antine where the pretreatment and post-treatment rates
of atrophy were compared, a treatment effect was ob-
served in right hippocampal atrophy, although all other
measures (whole brain, ventricular, left hippocampal)
showed no treatment effects [40]. This was not confirmed
in a larger, multicentre double-blinded and placebo-
controlled trial [41], leading to the possibility that this sur-
prising finding in the open-label study might be a false
positive. This concern is supported by the fact that the
pretreatment rate of right hippocampal atrophy (10.8%) is
much larger than the 4 to 5% typically seen in most AD
studies. Atrophy rates of this magnitude would be outside
what would normally be expected and would not be com-
patible with cross-sectional results [42]. Hippocampal
asymmetry in AD is an ongoing research area [43,44], with
different findings possibly due to different segmentation
protocols and algorithms. In the open-label study, add-
itional post-hoc analysis was performed to test this finding,
including the removal of outliers, and the significant de-
crease in right hippocampal atrophy was still present.
The unexpected findings of increased brain volume
loss (and/or ventricular expansion) have been of great
interest in the community and will probably impact the
design of upcoming trials. These findings occur across
multiple studies, although they often do not quite reach
statistical significance, as these effect sizes have been
relatively small. The strongest evidence for these ‘coun-
terintuitive’ treatment-related effects is in increased ven-
tricular expansion, which has the most sensitivity but
least specificity to AD. One of the most important un-
answered questions around these findings is whether this
is a transient effect, as there are not enough long-term
follow-up data to determine whether atrophy later slows
or remains increased compared with placebo.
There are numerous important aspects to consider
with regards to trial design for volumetric magnetic res-
onance analysis. The first is what type of measure is go-
ing to be used. Manual measures require expert training,
but can still result in high variability in the measure-
ment, especially in structures such as the hippocampi.
Automated measures help reduce this variability, espe-
cially with constraints built in to enforce consistency
longitudinally, but these methods could introduce bias.
Another critical decision is which statistical analysis to
use in the plan, as can be illustrated by the results from
the multicenter phase III Alphase study on tramiprosate.
The initial model, as specified in the trial protocol, re-
sulted in a treatment effect of increased hippocampal at-
rophy over a 78-week duration. However, this model
indicated very strong site effects, and a post-hoc analysismodel including key covariates showed a treatment ef-
fect in the opposite, expected direction of decreased
atrophy [45,46].
Positron emission tomography imaging of amyloid
deposition
Amyloid imaging provides an attractive option to show
efficacy in therapies that target removal of amyloid. A
PIB substudy of a phase II bapineuzumab trial acquired
data at two expert PET centres. The bapineuzumab arm
had a reduction in the standard uptake value ratio of
0.09 compared with the placebo arm, which showed a
0.15 increase [47]. These results were not replicated in
phase III studies, which enrolled a larger number of sub-
jects from a larger number of sites. While there was still
a significant difference in the carrier trial, it was a
smaller effect than in the phase II study. In the noncar-
riers there was no difference in the standard uptake
value ratio due to treatment [22]. Unlike other published
studies, the bapineuzumab trials contained eligibility cri-
teria requiring evidence of amyloid positivity on the
baseline PIB scan. As a result, 15% from the phase II
study and 6.5% of carriers and (a surprisingly high) 36%
of the noncarriers from the phase III study were below
the specified threshold and were excluded.
Another study on phenserine showed no significant
change in amyloid deposition from baseline at 3 months
or 6 months [48]. Results from a gantenerumab study at
three PET sites also showed some evidence of amyloid
removal. The placebo group had a 20% increase in the
standard uptake value ratio from baseline to end of
treatment, while the lower dose of treatment exhibited
only a slight increase of 5% and the high dose showed a
decrease in the standard uptake value ratio of 15% [24].
Current phase III studies of gantenerumab in AD are
ongoing. Two large phase III clinical trials have used the
fluorinated tracer AV-45 in substudies. Both semagace-
stat and solaneuzumab showed no treatment effects on
amyloid deposition [29,30]. As amyloid imaging is used
in larger studies with more sites, quality control and as-
surance procedures will become critical to remove sources
of variability that could mask a true treatment effect.
Positron emission tomography imaging of glucose
metabolism
FDG-PET has not been used as frequently as structural
MRI or amyloid PET in large multicentre trials. For a
more thorough review on FDG use in multicentre clin-
ical trials in dementia, see the review by Herholz and
colleagues [49]. One of the most promising signals from
that review was on the pilot study involving intranasal
insulin, where hypometabolism was reduced in subjects
with AD [50]. Based in part on the results of that study,
a larger phase II/III study was launched and is ongoing
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in the review, there were no treatment effects on FDG in
the phase III semagacestat study.
Prodromal Alzheimer’s disease/mild cognitive impairment
trials
Recent clinical trials in symptomatic patients with prob-
able AD have failed to show substantial evidence of clin-
ical benefit, but there have been observations of decreased
amyloid burden at autopsy or on amyloid imaging in
treated patients. These results have fostered the view that
clinically meaningful disease modification may be possible
if treatment begins at an earlier part of the disease process,
because intervention may be too late once downstream
neurodegeneration has become established. A number of
clinical trials have enrolled individuals who do not fulfil
criteria for dementia but are thought to have AD as the
underlying cause for their MCI, some of which are simul-
taneously enrolling trials in both mild to moderate AD
and MCI. New diagnostic criteria permit a diagnosis of
AD before dementia [51-53], with a growing emphasis on
the use of biomarkers to support the diagnosis. In these
trials, imaging will not only play a role as endpoints, but
also in the inclusion/exclusion criteria. Enrichment of tri-
als using imaging biomarkers is gaining acceptance; in
2011, the European Medical Agency issued a favourable
opinion on qualifying hippocampal volume as a method of
enrichment for prodromal AD trials [54]. Reducing het-
erogeneity of the population in terms of key biomarkers
could provide the needed power to make these studies
feasible and avoid situations where changes in amyloid are
being measured on trial participants, a subset of which are
amyloid-negative.
A few trials in MCI with imaging endpoints have com-
pleted and published their results. One of the earliest
was the InDDEx study, which tested whether rivastig-
mine delayed the onset of AD. The results showed a
treatment effect of reduction in ventricular enlargement
for rivastigmine at 12 and 24 months but not at the end
of treatment, and these findings did not survive correc-
tion for multiple comparisons [55]. Two studies investi-
gated the effect of donepezil: an Alzheimer’s Disease
Cooperative study on donepezil and vitamin E, which
showed no treatment effects, but a trend towards slow-
ing hippocampal atrophy in the APOE ε4 carriers [56];
and a substudy from another donepezil trial where no ef-
fects on hippocampal or entorhinal cortex atrophy were
found [57]. However, this latter study, which included
more subjects but involved a shorter follow-up duration,
did find treatment effects for whole brain volume, ven-
tricular enlargement and cortical grey matter volume.
Finally, a UK study using B vitamins showed a signifi-
cant treatment effect of a 30% reduction in the rate of
brain atrophy [58]. These results require confirmationbut may suggest that treatment earlier in the disease may
be more likely to show effects on imaging endpoints.
Preclinical prevention trials
In recent years there has been growing interest in begin-
ning treatment even earlier than MCI/prodromal AD. At
the MCI stage, the presence of cognitive deficits and im-
aging changes such as hippocampal atrophy suggest that
a considerable burden of pathology has already become
established. Thus, it may be necessary to intervene earlier
in the pathological cascade to prevent the development of
downstream, irreversible changes. This approach would be
more analogous to successful preclinical studies of amyloid-
modifying therapies in transgenic animal models, where
treatment is introduced when amyloid pathology is minimal
and there is no neurodegenerative phenotype [59].
The main challenge in prevention studies is to identify
cognitively normal individuals who are already accumu-
lating AD pathology. Frameworks for conceptualising
and defining the preclinical stage of AD have been de-
veloped that will aid in properly selecting patients for
these studies [60,61]. These frameworks are heavily reliant
on imaging endpoints, as multiple strands of evidence in-
dicate that the pathological changes of AD gradually
accrue over a period of many years before the onset of
symptoms [62,63]. Much of this research has been
done on familial AD mutation carriers, where a variety
of imaging abnormalities is observed during the pre-
symptomatic phase of disease. These abnormalities in-
clude early amyloid accumulation [63-65], regional
hypometabolism [63], atrophy [66,67], and alterations
to functional connectivity [68] and tissue microstruc-
ture [66,69]. All of these studies are reviewed in more
detail in [70].
A number of preclinical prevention trials for AD, ei-
ther in planning or recruiting, are based on two major
strategies in terms of population selection. The first
strategy is to recruit participants who are known to be
at increased genetic risk for AD – either because they
carry an autosomal dominant mutation that causes AD
or because they are a carrier of the ApoE ε4 allele. The
Dominantly Inherited Alzheimer Network is an inter-
national biomarker study of families affected by familial
AD with sites across the USA, Australia and Europe
[71]. The Dominantly Inherited Alzheimer Network has
launched a Trials Unit that is enrolling patients into a
double-blind placebo-controlled trial where participants
may receive either gantenerumab or solaneuzumab. Pri-
mary endpoints are changes in amyloid burden, as deter-
mined by PIB scans for the gantenerumab arm and by
CSF amyloid-beta levels in the solaneuzumab arm.
Secondary endpoints will involve further measures of
amyloid, rates of brain atrophy and changes on FDG-
PET imaging in key regions of interest, such as the
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follows a large Colombian kindred affected by the preseni-
lin 1 gene PSEN1 E280A mutation [72], will begin treat-
ment with crenezumab, another anti-amyloid monoclonal
antibody. This trial has cognitive primary outcome mea-
sures but imaging changes (PIB, structural MRI and FDG-
PET) will serve as secondary endpoints.
The second strategy is to recruit subjects that have high
risk for AD according to the recent definition of preclin-
ical AD. The A4 (Anti-Amyloid Treatment in Asymptom-
atic Alzheimer’s) study aims to enrol 1,000 cognitively
normal individuals aged 65 to 85 with evidence of amyloid
accumulation on amyloid PET imaging into a trial with
solanezumab [73]. This trial also has cognitive primary
endpoints but will assess changes on amyloid imaging,
volumetric MRI and CSF as secondary outcome measures.
All of the planned prevention trials will therefore collect
multiple biomarkers, providing complementary informa-
tion about the disease process and the potential effects of
intervention, with the hope that these will inform the es-
tablishment of surrogate endpoints for prevention trials in
the future [74].
Imaging’s role in dementia trials: regulatory guidance
All of the trials reviewed in this article are attempting to
collect substantial evidence for efficacy and safety, which
is required to obtain regulatory approval (for example,
by the US Food and Drug Administration). Historically,
the criterion for achieving this approval is to meet the
primary endpoint of two independent double-blind, placebo-
controlled phase III trials.
Realising the urgent need for disease-modifying treat-
ments, both the European Medicines Agency and the US
Food and Drug Administration have provided guidance
for drug development in AD and dementia [75,76]. While
both advocate for a co-primary endpoint design using one
cognitive and one functional (or global) endpoint, they
also recognise that improvement on these endpoints alone
could be a temporary, reversible effect that would not war-
rant a disease modification label for the drug. The current
guidance from the US Food and Drug Administration
states that they ‘are open to considering the argument that
a positive biomarker result (generally included as a sec-
ondary outcome measure in a trial) in combination with a
positive finding on a primary clinical outcome measure
may support a claim of disease modification’ [75].
Imaging measures, which provide information on the
underlying disease process, could be useful in providing
evidence for disease modification. However, there is cur-
rently not enough evidence to validate any imaging bio-
marker as a surrogate biomarker and potential primary
endpoint for a clinical trial [77]. There is also the risk of
a circular logic: imaging biomarkers may provide key
evidence of disease modification, but until we have atreatment that is truly disease modifying it is unclear
what its effect on imaging biomarkers will be.
Conclusions
Imaging is now used in clinical trials in AD at all stages of
disease and drug development. MRI is a prerequisite safety
outcome for some studies. The search for disease-modifying
therapies will increasingly incorporate multiple imaging end-
points to assess alterations in molecular pathology (for ex-
ample, amyloid and now tau imaging) and downstream
effects of neurodegeneration on structure (for example,
atrophy on MRI), function and connectivity (for example,
FDG-PET, functional MRI and diffusion imaging). Moving
to presymptomatic trials will increase the importance of
imaging and biomarkers. Ultimately, it will only be with
confirmation of a clinically useful disease modification ef-
fect that we will know the value of imaging endpoints.
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